X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761045
https://www.globenewswire.com//news-release/2024/02/21/2832750/33333/en/Coherus-Announces-U-S-Launch-of-UDENYCA-ONBODY-a-Novel-and-Proprietary-State-of-the-Art-Delivery-System-for-pegfilgrastim-cbqv.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761075
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761045
https://www.onclive.com/view/bla-resubmitted-to-fda-for-on-body-injector-presentation-of-pegfilgrastim-cbqv
https://www.indianpharmapost.com/news/aurobindos-subsidiary-to-withdraw-application-for-eu-marketing-authorization-of-two-biosimilars-14320
https://www.globenewswire.com/news-release/2023/03/06/2621056/33333/en/FDA-Approves-UDENYCA-Autoinjector.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761039
https://endpts.com/amgens-neulasta-gains-another-biosimilar-competitor-as-sales-slip/
https://www.fresenius-kabi.com/us/news/fresenius-kabi-receives-u-s-fda-approval-for-biosimilar
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761173
https://www.globenewswire.com/news-release/2022/08/29/2505800/0/en/BeyondSpring-Presents-New-Data-for-the-Use-of-Plinabulin-and-Pegfilgrastim-to-Decrease-Neutropenia-Burden-in-Peri-Transplant-Multiple-Myeloma-Patients-at-the-19th-International-Mye.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761084
https://www.ema.europa.eu/en/documents/overview/stimufend-epar-medicine-overview_en.pdf
https://www.globenewswire.com/news-release/2021/12/10/2350028/0/en/BeyondSpring-Pharmaceuticals-Announces-Analysis-of-New-Data-on-the-Plinabulin-Pegfilgrastim-Combination-in-Breast-Cancer-at-the-2021-San-Antonio-Breast-Cancer-Symposium.html
https://www.lupin.com/lupin-and-biomm-enter-into-a-distribution-and-marketing-agreement-for-pegfilgrastim-in-brazil/
http://www.pmlive.com/pharma_news/amgens_biosimilar_trends_report_shows_benefit_of_competition_from_biosimilars_1378822
https://www.fiercepharma.com/pharma/j-j-amgen-and-roche-face-growing-competition-from-biosimilars-are-driving-down-prices-report
https://www.forbes.com/sites/forbesfellows/2021/06/18/new-report-suggests-biosimliar-drugs-push-biologic-treatment-prices-lower/
https://www.globenewswire.com/news-release/2021/06/10/2245057/0/en/BeyondSpring-Announces-Final-Positive-Data-from-the-PROTECTIVE-1-Phase-3-CIN-Program-of-Plinabulin-as-a-Single-Agent-Compared-to-Pegfilgrastim-at-the-American-Society-of-Clinical-O.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761039
https://www.globenewswire.com/news-release/2021/06/08/2243453/0/en/BeyondSpring-Announces-a-Late-Breaking-Poster-Presentation-of-PROTECTIVE-2-Phase-3-Data-Showing-Plinabulin-in-Combination-with-Pegfilgrastim-Reverses-the-Immune-Suppressive-Effects.html
https://beyondspringpharma.com/beyondspring-announces-three-presentations-highlighting-positive-clinical-outcome-data-from-the-phase-3-program-of-plinabulin-in-combination-with-pegfilgrastim-for-the-prevention-of-chemotherapy-induc/?utm_source=rss&utm_medium=rss&utm_campaign=beyondspring-announces-three-presentations-highlighting-positive-clinical-outcome-data-from-the-phase-3-program-of-plinabulin-in-combination-with-pegfilgrastim-for-the-prevention-of-chemotherapy-induc
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761075
https://www.gabionline.net/Biosimilars/Research/Pelmeg-developed-with-aid-of-regulatory-reform
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125031
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125031
https://eyewire.news/articles/eyepoint-pharmaceuticals-presents-positive-data-of-yutiq-and-dexycu-in-four-poster-sessions-at-aao-2020/
https://www.globenewswire.com/fr/news-release/2020/09/24/2098615/0/en/New-Data-Highlights-BeyondSpring-s-Plinabulin-as-a-Highly-Effective-Agent-for-Preventing-Chemotherapy-Induced-Neutropenia-with-Potential-to-Reduce-Clinical-Resources-for-COVID-19.html
https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-september-2020
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761111
https://www.globenewswire.com/news-release/2020/06/02/2042178/0/en/BeyondSpring-E-Poster-Presented-at-2020-ASCO-Virtual-Scientific-Program.html
https://www.fresenius-kabi.com/news/fresenius-kabi-s-regulatory-submission-for-pegfilgrastim-biosimilar-accepted-for-review-by-EMA
https://www.bigmoleculewatch.com/2020/05/14/study-says-that-conversion-of-intermediate-risk-fn-patients-to-pegfilgrastim-biosimilar-likely-to-have-large-budget-impact/
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/biocon-mylan-launch-cancer-drug-in-canada/articleshow/75434205.cms
https://www.bigmoleculewatch.com/2020/03/17/pfizer-moves-to-dismiss-amgens-suit-over-proposed-neulasta-biosimilar/
https://www.raps.org/news-and-articles/news-articles/2019/12/us-biosimilar-launches-about-to-turn-a-corner
https://www.bigmoleculewatch.com/2020/02/12/amgen-sues-pfizer-over-proposed-neulasta-biosimilar/
https://economictimes.indiatimes.com/industry/healthcare/biotech/biocon-mylan-get-usfda-nod-for-pegfilgrastim-drug-substance-licence/articleshow/72253029.cms?from=mdr
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125031
https://www.ema.europa.eu/en/documents/overview/pegfilgrastim-mundipharma-epar-medicine-overview_en.pdf
https://endpts.com/us-biosimilar-launches-about-to-turn-a-corner/
Market Place
Share 
